BIOGEN INC. Cash Equivalents, at Carrying Value
BIOGEN INC. (BIIB) had Cash Equivalents, at Carrying Value of $2.51 billion as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashEquivalentsAtCarryingValue · last filed 2026-04-29
- 2026-03-31: Cash Equivalents, at Carrying Value $2.51B.
- 2025-12-31: Cash Equivalents, at Carrying Value $2.23B.
- 2025-09-30: Cash Equivalents, at Carrying Value $3.40B.
- 2025-06-30: Cash Equivalents, at Carrying Value $2.23B.
| Period end | Cash Equivalents, at Carrying Value |
|---|---|
| 2026-03-31 | $2.51B 10-Q · filed 2026-04-29 |
| 2025-12-31 | $2.23B 10-Q · filed 2026-04-29 |
| 2025-09-30 | $3.40B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $2.23B 10-Q · filed 2025-07-31 |
| 2025-03-31 | $2.11B 10-Q · filed 2025-05-01 |
| 2024-12-31 | $1.66B 10-K · filed 2026-02-06 |
| 2024-09-30 | $802.40M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $1.45B 10-Q · filed 2024-08-01 |
| 2024-03-31 | $484.80M 10-Q · filed 2024-04-24 |
| 2023-12-31 | $610.70M 10-K · filed 2025-02-12 |
| 2023-09-30 | $1.92B 10-Q · filed 2023-11-08 |
| 2023-06-30 | $2.26B 10-Q · filed 2023-07-25 |
| 2023-03-31 | $2.41B 10-Q · filed 2023-04-25 |
| 2022-12-31 | $2.85B 10-K · filed 2024-02-14 |
| 2022-09-30 | $3.19B 10-Q · filed 2022-10-25 |
| 2022-06-30 | $2.14B 10-Q · filed 2022-07-20 |
| 2022-03-31 | $1.28B 10-Q · filed 2022-05-03 |
| 2021-12-31 | $1.63B 10-K · filed 2023-02-15 |
| 2021-09-30 | $978.90M 10-Q · filed 2021-10-20 |
| 2021-06-30 | $1.18B 10-Q · filed 2021-07-22 |
| 2021-03-31 | $745.80M 10-Q · filed 2021-04-22 |
| 2020-12-31 | $626.90M 10-K · filed 2022-02-03 |
| 2020-09-30 | $1.57B 10-Q · filed 2020-10-21 |
| 2020-06-30 | $1.87B 10-Q · filed 2020-07-22 |
| 2020-03-31 | $1.97B 10-Q · filed 2020-04-23 |
| 2019-12-31 | $2.54B 10-K · filed 2021-02-03 |
| 2019-09-30 | $1.66B 10-Q · filed 2019-10-22 |
| 2019-06-30 | $1.12B 10-Q · filed 2019-07-24 |
| 2019-03-31 | $1.88B 10-Q · filed 2019-04-24 |
| 2018-12-31 | $705.50M 10-K · filed 2020-02-06 |
| 2018-09-30 | $1.90B 10-Q · filed 2018-10-23 |
| 2018-06-30 | $732.20M 10-Q · filed 2018-07-24 |
| 2018-03-31 | $3.77B 10-Q · filed 2018-04-24 |
| 2017-12-31 | $1.23B 10-K · filed 2019-02-06 |
| 2017-09-30 | $1.18B 10-Q · filed 2017-10-24 |
| 2017-06-30 | $836.00M 10-Q · filed 2017-07-25 |
| 2017-03-31 | $645.10M 10-Q · filed 2017-04-25 |
| 2016-12-31 | $2.04B 10-K · filed 2018-02-01 |
| 2016-09-30 | $1.74B 10-Q · filed 2016-10-26 |
| 2016-06-30 | $874.60M 10-Q · filed 2016-07-21 |
| 2016-03-31 | $820.60M 10-Q · filed 2016-04-21 |
| 2015-12-31 | $909.50M 10-K · filed 2017-02-02 |
| 2015-09-30 | $3.80B 10-Q · filed 2015-10-21 |
| 2015-06-30 | $974.00M 10-Q · filed 2015-07-24 |
| 2015-03-31 | $752.50M 10-Q · filed 2015-04-24 |
| 2014-12-31 | $716.30M 10-K · filed 2016-02-03 |
| 2014-09-30 | $663.30M 10-Q · filed 2014-10-22 |
| 2014-06-30 | $475.20M 10-Q · filed 2014-07-23 |
| 2014-03-31 | $236.10M 10-Q · filed 2014-04-23 |
| 2013-12-31 | $424.70M 10-K · filed 2015-02-04 |
| 2013-09-30 | $287.20M 10-Q · filed 2013-10-28 |
| 2013-06-30 | $261.50M 10-Q · filed 2013-07-25 |
| 2013-03-31 | $358.60M 10-Q · filed 2013-04-25 |
| 2012-12-31 | $439.40M 10-K · filed 2014-02-06 |
| 2012-09-30 | $309.00M 10-Q · filed 2012-10-25 |
| 2012-06-30 | $222.90M 10-Q · filed 2012-07-24 |
| 2012-03-31 | $161.40M 10-Q · filed 2012-05-01 |
| 2011-12-31 | $399.80M 10-K · filed 2013-02-05 |
| 2011-09-30 | $241.30M 10-Q · filed 2011-10-28 |
| 2011-06-30 | $440.60M 10-Q · filed 2011-07-26 |
| 2010-12-31 | $651.80M 10-K · filed 2012-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |